Ludwig Pichler

Ludwig Pichler

Auto-generated profile, based on publicly available information

Ludwig Pichler

Klinik Ottakring, 1160 Vienna, Austria

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in World Neurosurgery
Verified
Journal Article
Closed access
MMMatthias Millesi
Matthias Millesi
LPLudwig Pichler
Ludwig Pichler
CDChristoph Denk
Christoph Denk
JLJulius Lukas
Julius Lukas
CMChristian Matula
Christian Matula
LWLisa Irina Wadiura
Lisa Irina Wadiura

12 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LPLorenz Pichler
Lorenz Pichler
LPLudwig Pichler
Ludwig Pichler
MLMarkus Liu
Markus Liu
Stephan PayrStephan Payr
Stephan Payr
HBHarald Binder
Harald Binder
Thomas TiefenboeckThomas Tiefenboeck
Thomas Tiefenboeck
To investigate the functional outcome in young and athletic patients with ACL injuries, treated with an all-soft-tissue quadriceps tendon autograft at a minimum follow-up of 12 months. Methods: Patients who received a QT autograft ACL reconstruction between August 2018 and December 2020 were included in this study. Range of motion in the operated knee was described at 6 and 18 weeks after surgery and the functional outcome parameters (Lysholm score, IKDC score and Tegner activity scale) were calculated at 6 and ≥ 12 months after surgery. Results: Forty patients were included in this study, of which 29 identified as male and 11 as female. The average age was 31.3 years (range 16 to 57 years) and the mean follow-up time was 16.8 months (range 12 to 30 months). All functional outcome scores showed improvement over the course of the follow-up: Lysholm score 94.2 to 95.5 (n.s.), IKDC score 90.1 to 93.9 (n.s.), Tegner activity scale 3.7 to 5.0 (p > 0.001), all at six months and ≥12 months. No reruptures happened during the time of the follow-up. Conclusions: This study shows that the all-soft-tissue quadriceps tendon autograft technique can improve functional outcome in young and athletic patients with an ACL injury at short to intermediate follow-up.

1 November 2000 in Arzneimittelforschung
Verified
Journal Article
Closed access
PDF file
EMEva-Maria Muchitsch
Eva-Maria Muchitsch
KVKatalin Varadi
Katalin Varadi
LPLudwig Pichler
Ludwig Pichler
α1-Acid glycoprotein (AAG), a highly negatively charged glycoprotein, well known for its capillary stabilizing effect, was tested in rat models of acute edematous pancreatitis, acute hemorrhagic-necrotizing pancreatitis, and acute respiratory distress syndrome (ARDS). In cerulein-elicited edematous pancreatitis AAG improved histological alterations at 200 mg/ kg i.v. and plasma amylase activity at 1800 or 4200 mg/kg i.v. All other parameters (edema, plasma lipase) were not affected in a biologically relevant manner. In glycodeoxycholic acid-induced hemorrhagic-necrotizing pancreatitis AAG was without effect on parameters measured (plasma amylase, plasma lipase activity, histological scores) at 1800 or 4200 mg/kg i.v. At the extremely high dose of 15000 mg/kg i.v. plasma amylase and lipase levels were decreased. In lipopolysaccharide-mediated ARDS, AAG was tested at 50, 200 or 600 mg/kg i.v. AAG, but also the placebo formulation decreased the myeloperoxidase content in the bronchoalveolar lavage fluid. Histological alterations were improved by AAG, however, not by the placebo formulation. Lung water content was not significantly influenced by AAG, whereas Evans blue extravasation was significantly diminished by all three doses of AAG. It is concluded that the edematous pancreatitis is the first in vivo condition with increased extravascular fluid accumulation, in which AAG is not effective. Based on data presented here and literature data, there is evidence for a beneficial effect of AAG in acute lung injury. Wirkungen von α1-saurem Glykoprotein in Modellen akuter Pankreatitis und akuten Lungenversagens an Ratten α1-saures Glykoprotein (ASG) ist ein stark negativ geladenes Protein, das eine gefäßabdichtende Wirkung besitzt. In der vorliegenden Arbeit wurde die Wirkung von ASG in drei Modellen an der Ratte geprüft: akute ödematöse Pankreatitis, akute hämorrhagisch-nekrotisierende Pankreatitis und akutes Lungenversagen (ARDS). An der durch Caerulein-Infusion ausgelösten ödematösen Pankreatitis verhinderte ASG mit 200 mg/kg i.v. die morphologischen Veränderungen, mit 1800 und 4200 mg/kg i.v. wurde der Anstieg der Plasmaamylase mitigiert. Weitere Parameter wie Ödembildung und Plasmalipase-anstieg wurden praktisch nicht beeinflußt. In der durch Glykodeoxycholsäure-Injektion hervorgerufenen hämorrhagisch-nekrotisierenden Pankreatitis blieb ASG mit 1800 und 4200 mg/kg i.v. ohne Wirkung auf die Parameter Plasmalipase-, Plasmaamylaseaktivität sowie morphologische Veränderungen. Mit der sehr hohen Dosis von 15000 mg/kg i.v. wurden Plasmalipase und Plasmaamylase gesenkt. Das ARDS wurde durch Injektion von Lipopolysaccharid ausgelöst. ASG (50, 200 und 600 mg/kg i.v.) aber auch die Plazeboformulierung senkten den Myeloperoxidasegehalt in der bronchoalveolären Lavageflüssigkeit. Durch ASG, nicht aber durch die Plazeboformulierung, wurden die morphologischen Veränderungen hintangehalten. Während der Wassergehalt der Lunge durch ASG nicht signifikant beeinflußt werden konnte, wurde der Austritt von Evans Blau durch alle drei Dosen von ASG signifikant verringert. Somit stellt die ödematöse Pankreatitis das erste Modell dar, in dem in vivo kein antiödematöser/gefäßabdichtender Effekt von ASG gezeigt werden konnte. Gemeinsam mit Literaturbefunden weisen die vorliegenden Ergebnisse dagegen auf einen Schutzeffekt von ASG in Modellen des akuten Lungenversagens hin.